ARCA Pharmaceutical Competition

Indexes . USA . 
Index . ARCA Pharmaceutical
DRG Index   984.83  2.48  0.25%   
ARCA Pharmaceutical competes with Hafnia, Mind Medicine, Tscan Therapeutics, Western Acquisition, and Saia; as well as few others. Analyzing ARCA Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ARCA Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any index could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ARCA Pharmaceutical competition on your existing holdings.
Specify up to 10 symbols:

ARCA Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ARCA Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding indexs. A correlation of about +1.0 implies that the price of ARCA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ARCA Pharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
GZITF
+ 0.88
SAIA
SAIA
+ 0.81
MNMD
GZITF
+ 0.8
MNMD
TFII
+ 0.57
MNMD
TCRX
+ 0.55
HAFN
GZITF
+ 0.44
TFII
  
High negative correlations   
GZITF
- 0.85
HAFN
SAIA
- 0.85
HAFN
MNMD
- 0.8
HAFN
WAVS
- 0.58
HAFN
SAIA
- 0.5
TCRX
GZITF
- 0.45
TCRX

Risk-Adjusted Indicators

There is a big difference between ARCA Index performing well and ARCA Pharmaceutical Index doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ARCA Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

ARCA Pharmaceutical Competitive Analysis

The better you understand ARCA Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ARCA Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ARCA Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
DRG HAFN MNMD TCRX WAVS SAIA TFII GZITF
 0.25 
 984.83 
ARCA
 0.89 
 5.69 
Hafnia
 1.09 
 8.17 
Mind
 2.80 
 4.77 
Tscan
 0.91 
 10.92 
Western
 0.83 
 569.08 
Saia
 2.92 
 151.68 
TFI
 0.00 
 0.58 
Yuexiu
Market Volatility
(90 Days Market Risk)
Very steady
Slightly risky
Slightly risky
Slightly risky
Not too volatile
Very steady
Very steady
Abnormally volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
OK
Very Weak
Insignificant
Solid
Insignificant
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Very Low
Low
About Average
Average
Very Small
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Not Available
Buy
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Strong Hold
Strong Hold
Strong Hold
Strong Hold
Strong Buy
Strong Hold
Strong Hold
Current Ratio
N/A
13.86 X
7.53 X
0.01 X
1.58 X
1.27 X
0.72 X
Net Asset
3.91 B
124.54 M
272.15 M
3.41 M
2.58 B
6.28 B
35.66 B
Profit Margin
0.30 %
N/A
N/A
N/A
0.12 %
0.06 %
0.35 %
EBITDA
1.13 B
(92.57 M)
(80.1 M)
(961.77 K)
647.61 M
1.19 B
2.94 B
Operating Margin
0.16 %
N/A
(31.10) %
N/A
0.15 %
0.09 %
0.43 %
Current Valuation
5.31 B
328.15 M
73.81 M
37.6 M
15.43 B
15.99 B
2.81 B
Price To Book
1.92 X
2.29 X
1.11 X
201.69 X
6.78 X
4.66 X
0.61 X
Retained Earnings
631.02 M
(290.2 M)
(247.6 M)
(3.2 M)
1.66 B
1.65 B
N/A
Current Asset
N/A
N/A
N/A
N/A
158.99 M
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
1.76 %
N/A
Beta
0.084
2.33
0.78
-0.21
1.73
1.38
0.81
Number Of Employees
4 K
57
188
N/A
14 K
25.12 K
2.01 K
Shares Outstanding
508.1 M
73.33 M
49.09 M
3.42 M
26.6 M
84.63 M
1.67 B
Cash Flow From Operations
1.06 B
(64.36 M)
(61.36 M)
(940.73 K)
577.95 M
1.01 B
2.57 B
Annual Yield
0.12 %
N/A
N/A
N/A
N/A
0.01 %
0.12 %
Total Debt
1.29 B
14.13 M
92.43 M
204.22 K
138.71 M
2.34 B
13.22 B
Return On Equity
0.37
-0.55
-0.56
-0.29
0.18
0.17
0.11
Return On Asset
0.13
-0.25
-0.23
-0.15
0.11
0.0699
0.0283
Number Of Shares Shorted
50.32 K
10.05 M
2.3 M
212
2.18 M
640.03 K
N/A
Book Value Per Share
N/A
3.21 X
4.29 X
(0.96) X
84.13 X
32.52 X
6.71 X
Current Liabilities
N/A
N/A
N/A
N/A
141.38 M
N/A
N/A
Total Asset
3.91 B
124.54 M
272.15 M
3.41 M
2.58 B
6.28 B
35.66 B
Short Ratio
0.53 X
6.76 X
9.43 X
0.07 X
5.23 X
2.07 X
N/A
Last Dividend Paid
0.97
N/A
N/A
N/A
N/A
1.6
0.42
Target Price
N/A
26.63
12.57
N/A
510.16
162.75
N/A
Debt To Equity
N/A
N/A
0.04 %
5.87 %
0.10 %
0.73 %
1.15 %
Shares Owned By Institutions
19.90 %
68.11 %
85.73 %
27.08 %
99.82 %
74.68 %
16.62 %
Market Capitalization
4.27 B
605.72 M
254.58 M
37.4 M
15.13 B
12.84 B
982.59 M
Price To Earning
N/A
N/A
23.45 X
N/A
42.32 X
13.34 X
7.22 X
Price To Earnings To Growth
N/A
N/A
N/A
N/A
2.82 X
0.68 X
N/A
Price To Sales
1.60 X
N/A
27.19 X
N/A
4.77 X
1.55 X
0.28 X
Net Income
793.27 M
(95.73 M)
(89.22 M)
(1.03 M)
354.86 M
504.88 M
1.46 B
Earnings Per Share
N/A
(1.71) X
(0.95) X
(0.22) X
14.00 X
5.49 X
0.11 X
Shares Owned By Insiders
54.21 %
1.14 %
0.82 %
71.50 %
0.18 %
5.96 %
44.24 %
Revenue
2.67 B
N/A
21.05 M
N/A
2.88 B
7.52 B
3.7 B
Working Capital
271.64 M
71.63 M
164.42 M
(3.19 M)
326.64 M
269.89 M
N/A
Cash And Equivalents
N/A
105.74 M
125.6 M
618.56 K
137.87 M
133.14 M
2.92 B
Cash Per Share
N/A
3.71 X
5.22 X
0.04 X
5.24 X
1.53 X
1.74 X
Gross Profit
N/A
N/A
(46.28 M)
N/A
748.17 M
1.86 B
2.25 B
Day Typical Price
984.27
5.76
8.17
4.74
10.92
575.05
151.01
0.58
Accumulation Distribution
0.0063
0.0455
0.0594
0.087
N/A
0.0334
0.0208
N/A
Market Facilitation Index
6.23
0.27
0.5
0.43
N/A
19.66
3.16
N/A
Daily Balance Of Power
0.3981
0.1852
(0.18)
0.3023
(9,223,372,036,855)
0.2391
1.363924
0.0
Period Momentum Indicator
2.48
0.05
(0.09)
0.13
(0.10)
4.7
4.31
N/A
Rate Of Daily Change
1.0
1.01
0.99
1.03
0.99
1.01
1.03
1.0
Day Median Price
984.0
5.8
8.17
4.72
10.92
578.04
150.68
0.58
Price Action Indicator
2.08
(0.08)
(0.04)
0.11
(0.05)
(6.61)
3.16
N/A
Coefficient Of Variation
(399.99)
(627.32)
768.63
(1,808)
1858.06
461.47
3627.41
763.13
Mean Deviation
0.6296
1.8
3.56
2.8
1.06
2.18
1.34
0.8351
Total Risk Alpha
(0.34)
(0.77)
(0.18)
(0.82)
(0.23)
0.1503
(0.29)
(0.13)
Jensen Alpha
N/A
(0.39)
0.2098
(0.52)
0.1375
0.4315
(0.18)
0.3658
Sortino Ratio
N/A
N/A
0.1222
N/A
(0.01)
0.2415
(0.05)
N/A
Downside Variance
N/A
N/A
14.85
N/A
8.72
5.39
2.41
N/A
Standard Deviation
0.8034
2.31
4.68
3.65
1.93
3.22
1.99
3.29
Kurtosis
0.4683
(0.15)
0.6668
0.181
3.53
4.72
9.83
65.4
Potential Upside
1.02
3.44
9.76
6.1
3.35
5.11
2.92
N/A
Maximum Drawdown
3.6
9.2
24.75
17.54
12.07
17.45
12.09
26.67
Treynor Ratio
N/A
(3.63)
0.1965
(0.09)
(0.28)
0.3421
0.0255
0.9791
Variance
0.6455
5.36
21.88
13.29
3.74
10.38
3.98
10.8
Market Risk Adjusted Performance
N/A
(3.62)
0.2065
(0.08)
(0.27)
0.3521
0.0355
0.9891
Risk Adjusted Performance
(0.19)
(0.12)
0.1078
(0.03)
0.0472
0.1733
0.0272
0.1078
Skewness
(0.61)
0.3183
0.3353
0.2819
(0.1)
1.59
2.1
8.07
Semi Deviation
N/A
N/A
3.55
N/A
1.52
1.93
1.47
N/A
Information Ratio
(0.42)
(0.22)
0.1007
(0.09)
(0.02)
0.174
(0.04)
0.0892
Value At Risk
(1.53)
(4.15)
(5.75)
(5.05)
(3.25)
(3.95)
(2.96)
N/A
Expected Short fall
N/A
N/A
(4.52)
N/A
(2.05)
(2.61)
(1.48)
N/A
Downside Deviation
N/A
N/A
3.85
N/A
2.95
2.32
1.55
N/A
Semi Variance
N/A
N/A
12.63
N/A
2.31
3.72
2.15
N/A

ARCA Pharmaceutical Competition Performance Charts

Five steps to successful analysis of ARCA Pharmaceutical Competition

ARCA Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ARCA Pharmaceutical in relation to its competition. ARCA Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ARCA Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ARCA Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ARCA Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ARCA Pharmaceutical position

In addition to having ARCA Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Entertainment Thematic Idea Now

Entertainment
Entertainment Theme
Companies from entertainment industry including show business, news and media. The Entertainment theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
View All  Next Launch
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY